Last Updated: October 5, 2026

POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Potassium Phosphates In 0.9% Sodium Chloride patents expire, and when can generic versions of Potassium Phosphates In 0.9% Sodium Chloride launch?

Potassium Phosphates In 0.9% Sodium Chloride is a drug marketed by Amneal and Fresenius Kabi Usa and is included in two NDAs. There are two patents protecting this drug.

The generic ingredient in POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is potassium phosphate, dibasic; potassium phosphate, monobasic. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the potassium phosphate, dibasic; potassium phosphate, monobasic profile page.

DrugPatentWatch® Generic Entry Outlook for Potassium Phosphates In 0.9% Sodium Chloride

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE?
  • What are the global sales for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE?
  • What is Average Wholesale Price for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE?
Recent Clinical Trials for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mahidol UniversityN/A

See all POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE clinical trials

Pharmacology for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE

US Patents and Regulatory Information for POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE

POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is protected by two US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 218343-001 Jul 26, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Fresenius Kabi Usa POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-005 May 9, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Fresenius Kabi Usa POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-004 May 9, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Fresenius Kabi Usa POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-004 May 9, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Fresenius Kabi Usa POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-005 May 9, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.